EC Clinical and Medical Case Reports

Multiple myeloma (MM) is also known as skeletal related events and includes bone pain, osteoporosis, pathological fractures, osteolytic bone lesions, spinal instability, spinal cord and nerve root compression and extramedullary plasmacytoma. It is now generally accepted that patients with these complications usually require surgical management and that such treatment is safe and effective. The anaesthesiologist should continue the optimum supportive care received by these patients in the perioperative period also, by understanding the pathophysiology of the disease, the adverse effects of the chemotherapeutic agents and the guidelines for their supportive care. The aims of surgical interventions are to alleviate pain, improve quality of life, treat potential or existing pathological fractures, decompress the spinal cord and nerve roots, and reestablish bone continuity. Anaesthesia in such patients have important considerations. We report the perioperative management of a 55 years old female patient with MM and discuss the perioperative anaesthetic considerations scheduled for interlocking right humerus nailing.

Keywords: Multiple Myeloma; Interlocking Right Humerus; Anaesthesia; Fracture

1. Chavda S and Yong K. “Multiple myeloma”. British Journal of Hospital Medicine 2 (2017): C21-C27.
2. Rajkumar SV. “Updated Diagnostic Criteria and Staging System for Multiple Myeloma”. American Society of Clinical Oncology Educational Book 35 (2016): e418-e423.
3. Xu G-Q., et al. “Intramedullary nailing for pathological fractures of the proximal humerus caused by multiple myeloma: A case report and review of literature”. World Journal of Clinical Cases 11 (2022): 3518-3526.
4. Terps E., et al. “International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease”. The American Journal of Clinical Oncology 18 (2013): 2347-2357.
5. Riccomi G., et al. “Multiple myeloma in paleopathology: A critical review”. International Journal of Paleopathology 24 (2019): 201-212.
6. Cowan AJ., et al. “Diagnosis and Management of Multiple Myeloma: A Review”. The Journal of the American Medical Association 5 (2022): 464-477.
7. Mittelman M. “The Implications of Anemia in Multiple Myeloma”. Clinical Lymphoma, Myeloma and Leukemia 4 (2003): S23-S29.
8. Mikhael J., et al. “Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline”. Journal of Clinical Oncology 14 (2019): 1228-1263.
9. Lyman GH., et al. “American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer”. Blood Advances 4 (2021): 927-974.
10. Goldschmidt H., et al. “Multiple myeloma and renal failure”. Nephrology Dialysis Transplantation 3 (2000): 301-304.
11. Kundu S., et al. “Multiple Myeloma and Renal Failure: Mechanisms, Diagnosis, and Management”. Cureus 2 (2022): e22585.
12. Favà A., et al. “Treatment of multiple myeloma with renal involvement: the nephrologist’s view”. Clinical Kidney Journal 6 (2018): 777-785.
13. Meuser T., et al. “Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology”. Pain 3 (2001): 247-257.